CS
SUPN icon

Comerica Securities’s Supernus Pharmaceuticals SUPN Stock Holding History

Comerica Securities’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-246
Closed -$8.77K – 1294
2022
Q4 		$8.77K Buy
+246
New +$8.55K ﹤0.01% 1052

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Comerica Securities's SUPN Position: Q1 2023 in Review

Comerica Securities sold out of Supernus Pharmaceuticals (SUPN) in Q1 2023, closing a stake of 246 shares — an estimated $8.77K sold.

Comerica Securities first reported a position in SUPN in Q4 2022 and held it in 1 quarter. The position peaked at $8.77K in Q4 2022. 258 funds tracked by Wall St. Rank hold SUPN as of Q1 2023.

  • Comerica Securities reported no remaining Supernus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Comerica Securities sold 246 Supernus Pharmaceuticals shares in Q1 2023, an estimated $8.77K.
  • Comerica Securities first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Comerica Securities's Supernus Pharmaceuticals position peaked at $8.77K in Q4 2022.
  • 258 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.